EntryPoint Capital LLC Buys New Shares in Standard BioTools Inc. $LAB

Key Points

• EntryPoint Capital LLC has acquired a new stake in Standard BioTools Inc., purchasing 253,668 shares valued at approximately $274,000, representing 0.07% of the company.
• Other institutional investors have also increased their holdings in Standard BioTools, indicating growing interest, as hedge funds own 53.74% of the company's stock.
• Standard BioTools shares have shown a price increase, opening at $1.27, with a recent consensus rating of "Hold" and a price target of $1.55 set by analysts.

EntryPoint Capital LLC acquired a new stake in Standard BioTools Inc. (NASDAQ:LAB - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 253,668 shares of the company's stock, valued at approximately $274,000. EntryPoint Capital LLC owned about 0.07% of Standard BioTools at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Standard BioTools by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 168,777 shares of the company's stock worth $295,000 after acquiring an additional 7,304 shares during the period. HighTower Advisors LLC lifted its stake in shares of Standard BioTools by 10.8% in the 1st quarter. HighTower Advisors LLC now owns 102,791 shares of the company's stock worth $111,000 after acquiring an additional 10,000 shares during the period. Invesco Ltd. lifted its stake in shares of Standard BioTools by 7.5% in the fourth quarter. Invesco Ltd. now owns 175,041 shares of the company's stock valued at $306,000 after purchasing an additional 12,194 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in shares of Standard BioTools by 115.6% in the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company's stock valued at $29,000 after purchasing an additional 14,541 shares during the period. Finally, CWM LLC lifted its stake in shares of Standard BioTools by 101.8% in the first quarter. CWM LLC now owns 29,705 shares of the company's stock valued at $32,000 after purchasing an additional 14,984 shares during the period. 53.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on LAB shares. Cowen cut shares of Standard BioTools from a "buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Wall Street Zen upgraded shares of Standard BioTools from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Finally, TD Cowen cut shares of Standard BioTools from a "buy" rating to a "hold" rating and set a $1.55 price objective for the company. in a research note on Wednesday, August 13th. Three analysts have rated the stock with a Hold rating, According to MarketBeat, Standard BioTools currently has a consensus rating of "Hold" and a consensus price target of $1.55.

Insider Activity at Standard BioTools

In other news, Director Casdin Partners Master Fund, L purchased 125,000 shares of the stock in a transaction dated Tuesday, August 26th. The stock was acquired at an average cost of $1.26 per share, for a total transaction of $157,500.00. Following the completion of the acquisition, the director directly owned 60,275,000 shares in the company, valued at $75,946,500. This represents a 0.21% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have bought 883,220 shares of company stock worth $1,099,946 in the last ninety days. Insiders own 23.16% of the company's stock.

Standard BioTools Stock Performance

NASDAQ:LAB traded up $0.01 during mid-day trading on Thursday, hitting $1.29. 199,720 shares of the company's stock traded hands, compared to its average volume of 1,730,365. The firm's 50 day simple moving average is $1.29 and its 200 day simple moving average is $1.19. Standard BioTools Inc. has a 1 year low of $0.92 and a 1 year high of $2.32. The company has a market cap of $490.86 million, a PE ratio of -4.02 and a beta of 1.32.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.